Sign up for free ground shipping on all website orders, no minimum required, and get exclusive coupons!
Maximum quantity allowed is 999
CAS RN: 160807-49-8 | Product Number: I1118
Indirubin-3'-monoxime
Purity: >98.0%(HPLC)
- 3-(Hydroxyimino)[2,3'-biindolinylidene]-2'-one
- 3-[1,3-Dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one
- Indirubin-3'-oxime
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 50MG |
$238.00
|
Contact Us | Contact Us | 31 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | I1118 |
Purity / Analysis Method
|
>98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__1__6H__1__1N__3O__2 = 277.28 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Frozen (-20°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Light Sensitive,Air Sensitive,Heat Sensitive |
| CAS RN | 160807-49-8 |
| Reaxys Registry Number | 10094715 |
| Appearance | Light yellow to Brown powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 239.0 to 243.0 °C |
| NMR | confirm to structure |
| Melting Point | 241 °C |
| HS Number | 2933.79.8500 |
References
- 1) Indirubin, the active constituent of a Chinese antileukemia medicine, inhibits cyclin-dependent kinases
- 2) GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins
- 3) Antiproliferative and apoptosis inducing effects of indirubin-3'-monoxime in renal cell cancer cells
- 4) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
- 5) Development of LRRK2 Inhibitors for the Treatment of Parkinson’s Disease (a review)
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.
